SG11202003237QA - Bispecific antibodies and methods of making and using thereof - Google Patents

Bispecific antibodies and methods of making and using thereof

Info

Publication number
SG11202003237QA
SG11202003237QA SG11202003237QA SG11202003237QA SG11202003237QA SG 11202003237Q A SG11202003237Q A SG 11202003237QA SG 11202003237Q A SG11202003237Q A SG 11202003237QA SG 11202003237Q A SG11202003237Q A SG 11202003237QA SG 11202003237Q A SG11202003237Q A SG 11202003237QA
Authority
SG
Singapore
Prior art keywords
making
methods
bispecific antibodies
bispecific
antibodies
Prior art date
Application number
SG11202003237QA
Other languages
English (en)
Inventor
Yi Zhu
Katrina Bykova
Bill Brady
Blair Renshaw
Dong Xia
Zeren Gao
Brian Kovacevich
Jonathan K Fallon
phil Tan
Original Assignee
Systimmune Inc
Sichuan Baili Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systimmune Inc, Sichuan Baili Pharmaceutical Co Ltd filed Critical Systimmune Inc
Publication of SG11202003237QA publication Critical patent/SG11202003237QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202003237QA 2017-11-02 2018-11-01 Bispecific antibodies and methods of making and using thereof SG11202003237QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762580845P 2017-11-02 2017-11-02
PCT/US2018/058810 WO2019090002A1 (en) 2017-11-02 2018-11-01 Bispecific antibodies and methods of making and using thereof

Publications (1)

Publication Number Publication Date
SG11202003237QA true SG11202003237QA (en) 2020-05-28

Family

ID=66332369

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003237QA SG11202003237QA (en) 2017-11-02 2018-11-01 Bispecific antibodies and methods of making and using thereof

Country Status (11)

Country Link
US (1) US20200347137A1 (https=)
EP (1) EP3703736A4 (https=)
JP (1) JP7418326B2 (https=)
KR (2) KR102785809B1 (https=)
CN (2) CN117343193A (https=)
AU (1) AU2018358138C1 (https=)
CA (1) CA3069238A1 (https=)
IL (1) IL271346A (https=)
SG (1) SG11202003237QA (https=)
TW (1) TWI896517B (https=)
WO (1) WO2019090002A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3645738A4 (en) * 2017-06-25 2021-08-18 Systimmune, Inc. ANTI-PD-L1 ANTIBODIES AND METHOD FOR MANUFACTURING AND USING THEREOF
WO2021102131A1 (en) * 2019-11-21 2021-05-27 Brown University Bispecific antibodies against chi3l1 and ctla4 with enhanced cytotoxic effects on tumor cells
JP7802667B2 (ja) * 2019-12-04 2026-01-20 江蘇康寧杰瑞生物制薬有限公司 腫瘍治療のための二重特異性融合タンパク質
CN121712807A (zh) * 2023-08-31 2026-03-20 江苏恒瑞医药股份有限公司 Ctla4/tigit结合蛋白及其医药用途
WO2025061050A1 (en) * 2023-09-18 2025-03-27 Hanx Biopharmaceuticals, (Wuhan) Ltd. Antibodies targeting ctla4 and cd47 and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1492874B1 (en) * 2002-03-29 2011-01-19 XOMA Technology Ltd. Multigenic vector plasmids and methods for increasing expression of recombinant polypeptides
US8399618B2 (en) * 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
JP2008537941A (ja) * 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
CA2602663A1 (en) * 2005-03-31 2006-10-05 Xencor, Inc. Fc variants with optimized properties
KR101970025B1 (ko) * 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
JP6343011B2 (ja) * 2013-10-07 2018-06-13 プレステージ バイオファーマ プライベート リミテッド 抗体発現用バイシストロニック発現ベクター及びそれを用いた抗体の生産方法
CN104974253A (zh) * 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 抗ctla-4/pd-1双特异性抗体、其制备方法及应用
TWI716362B (zh) * 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
SG11201704741PA (en) * 2014-12-22 2017-07-28 Systimmune Inc Bispecific tetravalent antibodies and methods of makiing and using thereof
US10196445B1 (en) * 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
CN104987421A (zh) * 2015-05-13 2015-10-21 北京比洋生物技术有限公司 抗ctla-4和pd-1的双重可变结构域免疫球蛋白
US10954301B2 (en) * 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
CN106967172B (zh) * 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
JP2021502100A (ja) * 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体

Also Published As

Publication number Publication date
IL271346A (en) 2020-01-30
KR20200091382A (ko) 2020-07-30
RU2020108444A3 (https=) 2022-03-17
EP3703736A4 (en) 2021-11-03
KR20250044943A (ko) 2025-04-01
KR102785809B1 (ko) 2025-03-26
RU2020108444A (ru) 2021-12-02
JP7418326B2 (ja) 2024-01-19
EP3703736A1 (en) 2020-09-09
AU2018358138A1 (en) 2020-04-23
CN117343193A (zh) 2024-01-05
CN111212658B (zh) 2024-05-03
AU2018358138C1 (en) 2022-12-08
NZ763370A (en) 2024-10-25
TW201927819A (zh) 2019-07-16
CN111212658A (zh) 2020-05-29
WO2019090002A1 (en) 2019-05-09
TWI896517B (zh) 2025-09-11
US20200347137A1 (en) 2020-11-05
AU2018358138B2 (en) 2022-06-02
JP2021501575A (ja) 2021-01-21
CA3069238A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
IL279053A (en) Bispecific anti-PVRIG/ anti-TIGIT antibodies and methods of use
ZA201906730B (en) Anti-trem2 antibodies and methods of use thereof
IL273937A (en) Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
ZA201906757B (en) Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies
IL275070A (en) FCRN antibodies and methods of using them
SMT202300243T1 (it) Anticorpi anti-tigit e relativi metodi d'uso
IL268658A (en) Anti-tau antibodies and methods of use thereof
IL256086A (en) Anti-her2 antibodies and methods of use
SG11202000387YA (en) B7-h4 antibodies and methods of use thereof
DK3237005T3 (en) Bispecific tetravalent antibodies and methods of making and using thereof
SG11201912865VA (en) Multi-specific antibodies and methods of making and using thereof
SG11201912864SA (en) Multi-specific antibodies and methods of making and using thereof
SMT202400004T1 (it) Anticorpi fcrn e loro metodi di utilizzo
SG11201707886WA (en) Humanized anti-c1s antibodies and methods of use thereof
EP3661555C0 (en) BISPECIFIC ANTIBODIES AND THEIR USES
IL273538A (en) Anti-TRKB Monoclonal Antibodies and Methods of Use
IL274221A (en) Antibodies to ANTI-APOC3 and methods of use
SG11202003237QA (en) Bispecific antibodies and methods of making and using thereof
ZA202002144B (en) Antibodies and methods of use
PL3365367T3 (pl) Przeciwciała monoklonalne przeciwko pluskwom oraz metody ich wytwarzania i zastosowania
AU2015901092A0 (en) PAT-SM3 related antibodies and methods of making and using same